BioSpace News Archive

Drug Development

Portola Plunges After Hint of Delay for FDA Approval of Factor Xa-inhibitor

Shares of Portola Pharmaceuticals are falling after the company announced a delay of several months for possible regulatory approval of its Factor Xa-inhibitor antidote, AndexXa.

March 1, 2018
·
2 min read
·
Alex Keown
Business

Novartis and Pear Therapeutics Launch Collaboration Focused on Schizophrenia and Multiple Sclerosis

Novartis inked a collaboration deal with Pear Therapeutics to develop prescription digital therapeutics for schizophrenia and multiple sclerosis (MS).

March 1, 2018
·
2 min read
·
Mark Terry
Business

Mylan Teams Up with Revance Therapeutics to Develop Botox Biosimilar

Mylan N.V. signed a global collaboration and license deal with Revance Therapeutics to develop and market a biosimilar to Botox.

March 1, 2018
·
2 min read
·
Mark Terry
FDA

Sorrento Nabs FDA Approval for Shingles Pain Patch That Could Hit Blockbuster Status

Sorrento Therapeutics, Inc. nabbed regulatory approval for ZTlido, a non-opioid pain treatment in the form of a super-sticky patch.

March 1, 2018
·
2 min read
·
Alex Keown
Genetown

Rubius Therapeutics Raises $100 Million in Crossover Financing

Rubius Therapeutics has closed on an oversubscribed $100 million crossover financing.

March 1, 2018
·
2 min read
·
Mark Terry
Policy

U.S. Department of Justice to Take on Opioid Manufacturers and Distributors

With no end to the national opioid crisis in sight, the U.S. Department of Justice announced a plan to form a task force that will target opioid manufacturers and distributors.

March 1, 2018
·
3 min read
·
Alex Keown
Genetown

Finch Therapeutics Raises $36 Million Series B, Bringing Total to $77 Million

Finch Therapeutics closed on an oversubscribed Series B financing worth $36 million.

March 1, 2018
·
2 min read
·
Mark Terry
Genetown

Gelesis Secures $30 Million to Support Potential Approval of Weight Loss Drug

Boston-based Gelesis snagged $30 million to support potential manufacturing and commercialization of its anti-obesity drug.

March 1, 2018
·
2 min read
·
Alex Keown
BioMidwest

Blue Cross Blue Shield Health Index Identifies Top 10 Conditions Nationwide Affecting the Health of Commercially Insured

The BCBS Health Index encompasses more than 200 conditions that impact health and identifies those health conditions with the greatest impact on the commercially insured population.

March 1, 2018
·
5 min read
Avid Bioservices (NASD: CDMO) Selected to Provide Process Development and Clinical Manufacture for Novel Alzheimer’s Drug

Avid Bioservices was selected by Acumen Pharmaceuticals to lead process development and clinical manufacturing of novel alzheimer’s disease candidate.

March 1, 2018
·
4 min read